Amgen Inc.

NASDAQ Global Select
Back to all articles
Slightly Bearish -10

Amgen stock falls after HSBC downgrade and strong Q2 figures

AI-generated analysis

📉 Amgen stock closed down 1.34% at USD 377.35 after HSBC downgraded the rating from Buy to Hold.

📉 HSBC cut its price target to USD 425, citing that the stock has re-rated and trades near fair value.

📈 Q2 2026 revenue surged 9.5% year-over-year to reach USD 10.05 billion, beating consensus estimates.

💰 Diluted EPS of USD 6.29 exceeded analyst expectations of USD 5.62 by approximately USD 0.67 per share.

💊 Repatha revenue jumped 37% sequentially to USD 953 million, driven by volume growth of about 35%.

🔬 Upcoming MariTide obesity trial data is identified as the next major catalyst for investor interest.

📊 The consensus analyst price target of USD 381.68 suggests limited upside potential in the near term.

🏛️ Amgen's market capitalization was valued at USD 204.01 billion on September 11, 2026.

⚖️ Analyst sentiment remains balanced with a split of roughly one-third Buy ratings and over half Hold ratings.

Bullish Signals
  • Amgen reported Q2 2026 revenue of USD 10.05 billion, representing a 9.5% year-over-year increase that significantly beat consensus estimates.
  • Diluted earnings per share reached USD 6.29 in the second quarter, surpassing analyst expectations of USD 5.62 and growing 4.5% from the prior year.
  • The cholesterol-lowering drug Repatha generated USD 953 million in revenue for Q2 2026, driven by a 37% sequential increase and 35% volume growth.
  • Amgen maintains a substantial market capitalization of USD 204.01 billion, reflecting its strong position in the biopharma sector.
Risk Factors
  • HSBC downgraded Amgen from Buy to Hold and cut its price target to USD 425, arguing the stock has re-rated on strong execution.
  • The consensus analyst price target of USD 381.68 is only about USD 4 above the current share price, signaling limited near-term upside.
  • Amgen's stock closed roughly 15% below its 52-week high, indicating it has not yet recovered to previous peak valuations despite strong earnings.
Full Analysis
Amgen stock fell approximately 1.34% to close at USD 377.35 on September 11, 2026, following a downgrade from Buy to Hold by HSBC. The bank cut its price target to USD 425 from USD 445, arguing that the stock has re-rated significantly after strong execution and now trades close to fair value. This sentiment is reinforced by a consensus analyst price target of roughly USD 381.68, which sits only about USD 4 above the current share price, signaling limited near-term upside. Despite the negative analyst reaction, Amgen reported robust financial results for the second quarter of 2026. Revenue rose 9.5% year-over-year to reach USD 10.05 billion, surpassing consensus estimates of USD 9.43 billion. Diluted earnings per share also beat expectations, coming in at USD 6.29 compared to an analyst forecast of USD 5.62, representing a 4.5% increase from the prior-year quarter. Key growth drivers include the cholesterol-lowering drug Repatha, which generated USD 953 million in revenue during the quarter, up 37% sequentially. Analysts are now focusing on upcoming pipeline readouts, particularly data from the MariTide obesity trial, as the next major catalyst for the company amidst intensifying competition in the therapeutic space. The market capitalization of Amgen stood at USD 204.01 billion at the time of the close. While the stock remains well below its 52-week high of USD 447.03, it sits roughly USD 107 above its low. The prevailing analyst sentiment is balanced, with ratings split between Buy, Hold, and Sell categories, suggesting investors are weighing current earnings strength against future trial outcomes.